ONVO fundamentals
Key facts
Market capitalization75.04 MUSD
Basic EPS (TTM)−10.35USD
Founded2012
CEOKeith Murphy
Websiteorganovo.com
About
Organovo Holdings, Inc. is engaged in the development of bioprinted human tissues that emulate human biology and disease. Its three-dimensional human tissue platform is enabled by its proprietary NovoGen Bioprinters and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company was founded on January 30, 2012 and is headquartered in San Diego, CA.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
−76,000%
−59,000%
−42,000%
−25,000%
−8,000%
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
−3.90 M
−2.60 M
−1.30 M
0.00
1.30 M
Revenue
Net income
Net margin %
Revenue breakdown
Revenue streams and regions a business earns money from
Estimates
Revenue and Earnings forecasts and estimates accuracy
Dividends
Dividend yield, history and sustainability
ONVO does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company